The latest data from the Food and Drug Administration (FDA) reveals a remarkable public health achievement: youth tobacco use in the United States has fallen to historic lows. This progress is not accidental but the result of years of prevention efforts, stricter age restrictions, public education, and a collective commitment to keeping tobacco and nicotine products away from minors. Yet, despite this success, the challenge of adult smoking persists, requiring innovative solutions like FDA-authorized smoke-free alternatives.
According to the Centers for Disease Control and Prevention (CDC), cigarette smoking remains the leading cause of preventable death in the United States, with millions of adults continuing to smoke despite decades of warnings and cessation campaigns. While quitting entirely is always the best option, for adults who cannot or will not quit, scientifically substantiated smoke-free nicotine alternatives can play a crucial role in reducing harm.
This is where the FDA's recent decision on ZYN nicotine pouches becomes significant. After a thorough scientific review, the agency issued modified risk orders for 20 ZYN products, allowing them to be marketed with a clear, FDA-authorized claim: using ZYN instead of cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. Importantly, the FDA did not declare these products safe, nor did it encourage non-users to start using nicotine. Instead, it provided a tool to help adult smokers understand the relative risks of different products.
This distinction is crucial. Nicotine products are addictive and not risk-free, and they are not intended as cessation aids like patches or gum. But recognizing the differences in risk between combustible cigarettes and smoke-free alternatives is a science-based approach that can save lives. The latest youth data from the 2025 National Youth Tobacco Survey, analyzed by the FDA, show declines in use of tobacco products, combustible products, and e-cigarettes between 2022 and 2025. Youth nicotine pouch use remained low and stable, with only 1.7 percent of students reporting current use in 2025, down from 1.8 percent in 2024.
These numbers should reassure policymakers that protecting youth and providing adult alternatives are not mutually exclusive. The historic lows in youth tobacco use demonstrate that a regulated marketplace with smoke-free alternatives can coexist with strong youth prevention. However, continued vigilance is necessary. PMI U.S., the company behind ZYN, has implemented responsible marketing practices to ensure its products are only marketed to adults 21 and older. This includes featuring individuals aged 35 or older in advertising, requiring age verification on websites, limiting social media presence to age-restricted platforms, and refraining from influencer endorsements and product placement in movies or TV shows.
These practices are part of a broader 10-point approach to underage prevention, which includes retail support programs, real-world monitoring, and compliance checks like FDA mystery shopping. No single entity can solve this alone; it requires collaboration among regulators, retailers, manufacturers, parents, and public health leaders. The path forward is clear: keep nicotine products away from youth, enforce age restrictions, combat illicit products, and ensure responsible marketing.
The United States has made extraordinary strides in reducing youth tobacco use, but the work is not done. The next step is to apply the same seriousness to helping adult smokers transition to better alternatives. A mature tobacco policy must prevent youth initiation while supporting adult smokers in reducing their health risks. These goals are not in conflict; they belong together. By embracing this balanced approach, we can continue to protect young people while addressing the persistent burden of adult smoking.
